Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;42(6):702-707.
doi: 10.1038/s41372-022-01345-1. Epub 2022 Feb 22.

Population-based incidence and risk factors for cholestasis in hemolytic disease of the fetus and newborn

Jonas Teng  1   2 , Linnéa Wickman  3 , Marie Reilly  4 , Antal Nemeth  5   6 , Björn Fischler  5   6 , Kajsa Bohlin #  5   7 , Eleonor Tiblad #  3   8
Affiliations

Population-based incidence and risk factors for cholestasis in hemolytic disease of the fetus and newborn

Jonas Teng et al. J Perinatol. 2022 Jun.

Abstract

Objective: To estimate the incidence of cholestasis in neonates with hemolytic disease of the fetus and newborn (HDFN) and investigate risk factors and long-term liver disease.

Study design: A population-based cohort study of all infants born with HDFN within the Stockholm region between 2006 and 2015. The study period was the first 90 days of life, and presence of any chronic liver disease was evaluated at two years of age.

Results: Cholestasis occurred in 7% (11/149). Median age at detection was 1.1 days. Intrauterine blood transfusions and maternal alloimmunization with multiple red blood cell antibodies including D-, c- or K-antibodies were independent risk factors for cholestasis. No infant had chronic liver disease at two years of age.

Conclusions: Infants with severe HDFN have increased risk for cholestasis, particularly those requiring multiple intrauterine transfusions. Early and repeated screening for conjugated hyperbilirubinemia in the first week of life is needed to ensure adequate management.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Ree IMC, Smits-Wintjens V, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10:607–16. doi: 10.1080/17474086.2017.1331124. - DOI - PubMed
    1. Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008;48:941–52. doi: 10.1111/j.1537-2995.2007.01625.x. - DOI - PubMed
    1. Liu S, Ajne G, Wikman A, Lindqvist C, Reilly M, Tiblad E. Management and clinical consequences of red blood cell antibodies in pregnancy: a population-based cohort study. Acta Obstet Gynecol Scand. 2021;100:2216–25. - PubMed
    1. Singh B, Chaudhary R, Katharia R. Title: Effect of multiple maternal red cell alloantibodies on the occurrence and severity of Hemolytic Disease of the Fetus and Newborn. Transfus Apher Sci. 2021;60:102958. - PubMed
    1. Spong CY, Porter AE, Queenan JT. Management of isoimmunization in the presence of multiple maternal antibodies. Am J Obstet Gynecol. 2001;185:481–4. doi: 10.1067/mob.2001.115999. - DOI - PubMed

Publication types

LinkOut - more resources